In HFpEF, the benefit of empagliflozin on a composite of CV death or HF hospitalization at 26 mo did not vary by diabetes status

Marat Fudim; Harriette G C Van Spall

doi:10.7326/J22-0075

In HFpEF, the benefit of empagliflozin on a composite of CV death or HF hospitalization at 26 mo did not vary by diabetes status

Ann Intern Med. 2022 Oct;175(10):JC111. doi: 10.7326/J22-0075. Epub 2022 Oct 4.

Authors

Marat Fudim¹, Harriette G C Van Spall²

Affiliations

¹ Duke University, Durham, North Carolina, USA (M.F.).
² McMaster University, Hamilton, Ontario, Canada (H.G.S.).

PMID: 36191324
DOI: 10.7326/J22-0075

Abstract

Filippatos G, Butler J, Farmakis D, et al. Empagliflozin for heart failure with preserved left ventricular ejection fraction with and without diabetes. Circulation. 2022;146:676-86. 35762322.

Publication types

Comment

MeSH terms

Benzhydryl Compounds
Diabetes Mellitus* / drug therapy
Glucosides
Heart Failure* / drug therapy
Hospitalization
Humans
Stroke Volume
Ventricular Function, Left

Substances

Benzhydryl Compounds
Glucosides
empagliflozin